Evidence-Based Surfactant Therapy for Preterm Infants Final rept. (Sept 30 1999-Sept 29 2003)

摘要

The introduction in the early 1990's of surfactant therapy for the prevention and treatment of neonatal respiratory distress syndrome, RDS, has resulted in reductions in both mortality and morbidity for preterm infants. However, despite the availability of high quality research, including numerous randomized controlled clinical trials, a substantial gap remains between the practices supported by the research evidence and those in routine clinical use. In particular, although the evidence supports prophylactic administration of surfactant in the delivery room for infants at highest risk for RDS and supports early administration of surfactant to infants with established RDS before severe respiratory failure develops, relatively few infants currently receive delivery room treatment and many infants with RDS receive treatment that is delayed for several hours after birth.